https://nova.newcastle.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 Assessing the impact of law enforcement to reduce over-the-counter (OTC) sales of antibiotics in low- and middle-income countries; a systematic literature review https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45241 Wed 26 Oct 2022 20:02:43 AEDT ]]> Noncommunicable diseases, access to essential medicines and universal health coverage https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:42167 Wed 13 Mar 2024 09:41:25 AEDT ]]> Mandatory disclosure of pharmaceutical industry-funded events for health professionals https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:6943 Wed 11 Apr 2018 18:38:10 AEST ]]> Costs of medicines and health care: a concern for Australian women across the ages https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:14771 Wed 11 Apr 2018 16:01:48 AEST ]]> Health systems and sustainability: doctors and consumers differ on threats and solutions https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:14312 Wed 11 Apr 2018 15:21:32 AEST ]]> Medicines availability for non-communicable diseases: the case for standardized monitoring https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:28263 Wed 11 Apr 2018 14:39:13 AEST ]]> The health services burden of heart failure: an analysis using linked population health data-sets https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:13534 Wed 11 Apr 2018 14:07:47 AEST ]]> Does it matter who writes medical news stories? https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:8456 Wed 11 Apr 2018 13:48:59 AEST ]]> Medicines and the media: news reports of medicines recommended for government reimbursement in Australia https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:14800 = 20 news reports (total 2350 stories); nine of these cost more than AU$10,000 per course or year of treatment. For these 18 medicines, 31% of stories appeared in the six months prior to the PBAC meeting, 14% in the meeting month and 33% in the six months post-meeting. 38% of the stories had >= 3 medicine mentions, 37% referred to the PBS, 24% to cost to the patient, and 9% cost to Government. There was active patient lobby group campaigning in support of listing of infliximab and pemetrexed; the stories for ADHD were often more negative, referring to the dangers of the medicines and sometimes questioning the appropriateness of treatment and public subsidy. There was little discussion of the PBAC's evidence-based decision-making processes. Conclusions: While there was no general trend to increased news reporting associated with PBAC meetings, some drugs did attract media attention. With more new and expensive drugs, decisions on public funding will become increasingly difficult. The media have an important role in enhancing public understanding of the issues around resource allocation. Specialist journalists, guidelines and checklists may help reporting.]]> Wed 11 Apr 2018 11:22:54 AEST ]]> Medicines for cancers in children: the WHO model for selection of essential medicines https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:28260 Wed 11 Apr 2018 11:22:34 AEST ]]> Do computerised clinical decision support systems for prescribing change practice?: a systematic review of the literature (1990-2007) https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:6940 Wed 11 Apr 2018 09:50:28 AEST ]]> The role of evidence in consumer choice of non-prescription medicines https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44248 U-test) were used to explore associations between responses and previous experience with medicines. Key findings: The most important factors when purchasing NPMs were effectiveness and safety. However, personal experience was the most common method of determining effectiveness. Most respondents believed buying NPMs in pharmacies gave access to advice, but were less likely to agree that pharmacies were associated with safe and effective treatments. Around half the respondents agreed that it is wrong to sell treatments lacking scientific evidence; many also agreed that it is up to consumers to decide what they want even without scientific evidence. Individuals experiencing an ineffective NPM were less likely to trust scientific evidence of efficacy as the sole source of effectiveness information; regular prescription medicine users often agreed that scientific evidence is needed to support effectiveness. Conclusions: Consumers have conflicting views regarding the need for scientific evidence and the desire for patient autonomy in NPM purchases. This presents a challenge for pharmacists wishing to maintain professional obligations to provide evidence-based treatments to consumers.]]> Tue 11 Oct 2022 12:14:38 AEDT ]]> A quantitative analysis of the quality and content of the health advice in popular Australian magazines https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:26789 Tue 01 May 2018 15:44:52 AEST ]]> Access to cytotoxic medicines by children with cancer: a focus on low and middle income countries https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:24082 Thu 28 Oct 2021 13:02:20 AEDT ]]> Response rates and representativeness: a lottery incentive improves physician survey return rates https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:533 Thu 25 Jul 2013 09:10:31 AEST ]]> Variations in the Consumption of Antimicrobial Medicines in the European Region, 2014–2018: Findings and Implications from ESAC-Net and WHO Europe https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53404 Thu 23 Nov 2023 13:44:19 AEDT ]]> Health care spending: changes in the perceptions of the Australian public https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:28262 Thu 13 Jan 2022 10:30:51 AEDT ]]> Essential medicines for cancer: WHO recommendations and national priorities https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:28261 Thu 09 Dec 2021 11:04:21 AEDT ]]> What essential medicines for children are on the shelf? https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:6939 Sat 24 Mar 2018 10:46:37 AEDT ]]> Computerized clinical decision support for prescribing: provision does not guarantee uptake https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:11391 Sat 24 Mar 2018 10:32:33 AEDT ]]> Medication reconciliation at two teaching hospitals in Australia: a missed opportunity? https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:31226 Sat 24 Mar 2018 08:43:19 AEDT ]]> Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:7012 Sat 24 Mar 2018 08:38:05 AEDT ]]> Australia's pharmaceutical cost sharing policy: reducing waste or affordability ? https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:7008 Sat 24 Mar 2018 08:37:49 AEDT ]]> Health news in the media: a dose of critical thinking is the best treatment https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:8455 Sat 24 Mar 2018 08:33:35 AEDT ]]> The impact of specialists on prescribing by general practitioners https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1101 Sat 24 Mar 2018 08:31:58 AEDT ]]> The influence of specialists on prescribing GPs: a qualitative study https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1824 Sat 24 Mar 2018 08:31:23 AEDT ]]> The role of pharmacoeconomics in formulary decision-making: considerations for hospital and managed care pharmacy and therapeutics committees https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:3028 Sat 24 Mar 2018 08:30:01 AEDT ]]> Personal formularies: an index of prescribing quality? https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1206 Sat 24 Mar 2018 08:28:39 AEDT ]]> Limitations of Health Insurance Commission (HIC) data for deriving prescribing indicators https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1441 Sat 24 Mar 2018 08:28:08 AEDT ]]> Moral hazard and prescription medicine use in Australia: the patient perspective https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:1750 Sat 24 Mar 2018 08:27:28 AEDT ]]> Low awareness of adverse drug reaction reporting systems: a consumer survey https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:14683 Sat 24 Mar 2018 08:19:09 AEDT ]]> Computerised prescribing: assessing the impact on prescription repeats and on generic substitution of some commonly used antibiotics https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:10532 Sat 24 Mar 2018 08:13:56 AEDT ]]> The impact of pharmacy computerised clinical decision support on prescribing, clinical and patient outcomes: a systematic review of the literature https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:10039 Sat 24 Mar 2018 08:12:26 AEDT ]]> Pharmaceutical industry funding of educational events for pharmacists in Australia: an analysis of data from the first 6 months of a mandatory disclosure programme https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:10038 Sat 24 Mar 2018 08:12:00 AEDT ]]> Oximes for acute organophosphate pesticide poisoning https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:12274 Sat 24 Mar 2018 08:10:12 AEDT ]]> Electronic information and clinical decision support for prescribing: state of play in Australian general practice https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:18164 90% of general practices computerized. Recent eHealth incentives promote the use of up to date electronic information sources relevant to general practice with flexibility in mode of access. Objective: To determine GPs’ access to and use of electronic information sources and computerized clinical decision support systems (CDSSs) for prescribing. Methods: Semi-structured interviews were conducted with 18 experienced GPs and nine GP trainees in New South Wales, Australia in 2008. A thematic analysis of interview transcripts was undertaken. Results: Information needs varied with clinical experience, and people resources (specialists, GP peers and supervisors for trainees) were often preferred over written formats. Experienced GPs used a small number of electronic resources and accessed them infrequently. Familiarity from training and early clinical practice and easy access were dominant influences on resource use. Practice time constraints meant relevant information needed to be readily accessible during consultations, requiring integration or direct access from prescribing software. Quality of electronic resource content was assumed and cost a barrier for some GPs. Conclusions: The current Australian practice incentives do not prescribe which information resources GPs should use. Without integration into practice computing systems, uptake and routine use seem unlikely. CDSS developments must recognize the time pressures of practice, preference for integration and cost concerns. Minimum standards are required to ensure that high-quality information resources are integrated and regularly updated. Without standards, the anticipated benefits of computerization on patient safety and health outcomes will be uncertain.]]> Sat 24 Mar 2018 08:04:39 AEDT ]]> Pharmaceutical Benefits Scheme cost sharing, patient cost consciousness and prescription affordability https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:16505 Sat 24 Mar 2018 08:04:17 AEDT ]]> Bladder carcinoma in situ (CIS) in Australia: a rising incidence for an under-reported malignancy https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:18447 50 years, showing a rapid increase in the rates of CIS from 2001. * There was an 11% (P = 0.04) and 14% (P = 0.02) annual increase in incidence of CIS in men and women and these rates increased with age. Conclusions * National data (AIHW) substantially underestimate the incidence of CIS in the Australian population. * Patient level data suggest CIS rates are rapidly increasing in Australia despite high treatment rates. * Closer surveillance and awareness of these high rates warrants further study and we recommend that CIS be considered a reportable disease.]]> Sat 24 Mar 2018 07:59:46 AEDT ]]> Prescription medicines: decision-making preferences of patients who receive different levels of public subsidy https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:19176 Sat 24 Mar 2018 07:52:18 AEDT ]]> Exploring the role of clinical self-audits as a professional development tool https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:5641 Sat 24 Mar 2018 07:44:00 AEDT ]]> Moral hazard and prescription medicine use in Australia - the patient perspective https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:138 Sat 24 Mar 2018 07:43:13 AEDT ]]> Studies using australia's pharmaceutical benefits scheme data for pharmacoepidemiological research: a systematic review of the published literature (1987-2013) https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:27972 Sat 24 Mar 2018 07:38:44 AEDT ]]> Prevention of postpartum haemorrhage: cost consequences analysis of misoprostol in low-resource settings https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22651 Sat 24 Mar 2018 07:16:40 AEDT ]]> Shortages and price variability of essential cytotoxic medicines for treating children with cancers https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:42358 Mon 22 Aug 2022 14:01:34 AEST ]]> Antimicrobial medicines consumption in Eastern Europe and Central Asia - an updated cross-national study and assessment of quantitative metrics for policy action https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36795 Mon 06 Jul 2020 15:22:42 AEST ]]> Poor availability of essential medicines for women and children threatens progress towards sustainable development goal 3 in Africa https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:42591 Fri 26 Aug 2022 09:08:17 AEST ]]>